Denecimig shows consistent safety and efficacy across age groups in h…

Denecimig, Novo Nordisk's subcutaneous non-factor hemophilia A therapy, showed consistent safety and efficacy across paediatric and adult cohorts in the FRONTIER4 extension trial (426 participants), with 89% of children achieving zero treated bleeds and annualized bleeding rates of 0.37 for children and 0.75 for adults. The drug, under FDA review via BLA submitted September 2025, offers dosing flexibility (once-weekly to once-monthly) and age coverage starting at one year, differentiating it from competitors like emicizumab and concizumab. Denecimig's label will cover children as young as one year old on flexible dosing—emicizumab and concizumab don't. If you're building switching infrastructure, patient support tools, or outcomes tracking for haemophilia clinics, you need to know that Novo Nordisk is about to take market share from an entrenched competitor, and clinicians will need help managing the transition.